Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05801107
- Locations
- 🇨🇳
Shanghai Jiao Tong University Chest Hospital, Shanghai, China
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05799820
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1220
- Registration Number
- NCT05758519
- Locations
- 🇨🇳
Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China
Single Dose Mass Balance Study With [14C]Iruplinalkib (WX-0593) In Healthy Male Volunteers
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05716126
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT05703204
- Locations
- 🇨🇳
Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 650
- Registration Number
- NCT05690945
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05689203
- Locations
- 🇨🇳
Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China
A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT05649761
- Locations
- 🇨🇳
Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 474
- Registration Number
- NCT05629949
- Locations
- 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences, Beijing, China
Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 216
- Registration Number
- NCT05621330
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Shandong, China
© Copyright 2024. All Rights Reserved by MedPath